Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
HIV, lenacapavir and Hetero Drugs
Indian pharma firms sign deal to produce, sell generic HIV drug lenacapavir
Indian pharmaceutical companies are set to produce generic versions of lenacapavir, an HIV prevention drug, under agreements with US-based Gilead Sciences to distribute it in 120 resource-limited countries.
Indian pharma firms ink deal with U.S. drug maker Gilead to make, market generic HIV drug lenacapavir
Dr. Reddy's, Hetero, and Mylan partner with Gilead Sciences to manufacture generic lenacapavir for HIV prevention globally.
Hetero Inks Voluntary Licensing Pact with Gilead for HIV Drug Lenacapavir
Hetero has partnered with Gilead Sciences to manufacture and distribute the HIV drug lenacapavir in 120 low- and middle-income countries, aiming to improve access to treatment and prevention. Lenacapavir,
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries.
Biopharma firm Gilead announces lenacapavir licensing for HIV treatment
International AIDS Society, an association of HIV/AIDS professionals, applauded moves by Gilead Sciences, a biopharma company, to make the generic injectable lenacapavir for HIV prevention widely available,
Queerty on MSN
1d
More good news about the twice-yearly PrEP injection
Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has been testing it as an injectable form ...
The Pharma Letter
1d
Efficacy and safety data show strong reduction in HIV infections with lenacapavir
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an ...
2d
Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir
Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in ...
BMJ
2d
Gilead to license generic lenacapavir for HIV prophylaxis in 120 lower income countries
Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...
Managed Healthcare Executive
5d
Gilead to Distribute Lenacapavir in Top HIV Countries, Critics Unhappy
The twice yearly lenacapavir injection will be available in 120 countries with a series of regulatory filings beginning by ...
Devex
23h
Devex Newswire: HIV prevention has game-changing tools, but access lags
Former U.K. foreign aid officials' advice to Prime Minister Keir Starmer. Plus time is running out for the U.N.'s “failing ...
BioSpace
6d
Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...
4d
Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation
Discover why Gilead Sciences is a strong buy with potential blockbuster drugs in HIV and oncology, favorable valuation, and a ...
unaids
7d
UNAIDS response to Gilead’s announcement on signing voluntary licensing agreements on lenacapavir with six generic manufacturers
We welcome Gilead’s statement of commitment to non-profit pricing, but we had been waiting eagerly for a specific price. We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Gilead Sciences
HIV
Pre-exposure prophylaxis
Feedback